This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
by Zacks Equity Research
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Medidata (MDSO) to be Acquired by Dassault for $5.8 Billion
by Zacks Equity Research
Dassault's acquisition of Medidata (MDSO) to close by 2019-end.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $139.78, moving +0.55% from the previous trading session.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Chevron, Adobe, Las Vegas Sands and Southern Copper
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Celgene & Acceleron's BLA for Luspatercept Accepted by FDA
by Zacks Equity Research
Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.
Top Stock Reports for Johnson & Johnson, Chevron & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Chevron (CVX) and Adobe (ADBE).
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $134.46, marking a +0.55% move from the previous day.
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
New Trade Concerns Rattle the Markets
by David Borun
President Trump announces new tariffs on Mexican imports and the equity market sink
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $132.12, moving +0.6% from the previous trading session.
Allergan's (AGN) Vraylar Gets FDA Nod for Bipolar Depression
by Zacks Equity Research
Allergan's (AGN) sNDA for Vraylar gets the FDA approval for the treatment of adult patients with major depressive episodes related to bipolar I disorder.
Teva Settles With Oklahoma, Shares Fall Following Downgrade
by Zacks Equity Research
Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.
Geron Stock Up More Than 50% in 2019 So Far: Here's Why
by Zacks Equity Research
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
J&J Stock Up This Year So Far: Will the Momentum Continue?
by Zacks Equity Research
J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.
Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
by Kinjel Shah
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
by Swarup Gupta
The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.
J&J's Invokana sNDA Gets Priority Review Status From FDA
by Zacks Equity Research
FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $138.76, moving +0.46% from the previous trading session.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
AbbVie's Brain Cancer Candidate Fails in Phase III Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Top Analyst Reports for Johnson & Johnson, Apple & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Apple Inc. (AAPL) and The Goldman Sachs Group, Inc. (GS).
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
by Kinjel Shah
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs